Patient centric drug product design provides an opportunity to increase safety and effectiveness. Fundamental understanding of the relationship between drug concentration and pharmacological effect allows definition of a target exposure profile. Once defined for a given disease target,the feasibility of achieving the target exposure profile can be assessed through molecular and/or formulation design, leading to selection of candidate drugs with the right balance of pharmacological, safety and pharmaceutical/ADME properties. This session will include 2 talks and a panel discussion on the application of PKPD modelling and in-vitro safety screening in discovery and early clinical development.
Venue:
Alderley Park Conference
Location: Alderley Park
Country: United Kingdom
Organiser Contact Details:
ELRIGT:
07484 113971info@elrig.org
Alderley Park Conference